Cardiol Therapeutics (CRDL) Interest Expenses (2021 - 2022)
Cardiol Therapeutics (CRDL) posted Interest Expenses of $111903.7 for Q4 2022, down 45.26% on a QoQ basis from $204425.3 in Q4 2021, and down 45.26% year-over-year from $204425.3 in Q4 2021.
Cardiol Therapeutics (CRDL) Interest Expenses (2021 - 2022) Analysis & Trends
Cardiol Therapeutics' Interest Expenses history runs 2 years deep, the most recent figure standing at $111903.7 for Q4 2022.
- Quarterly Interest Expenses fell 45.26% year-over-year to $111903.7 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $111903.7 (down 45.26% YoY) and the FY2022 annual result came in at $111903.7, down 45.58% from the prior year.
- Interest Expenses was $111903.7 for Q4 2022 at Cardiol Therapeutics, down from $204425.3 in the prior quarter.
- Across five years, Interest Expenses topped out at $204425.3 in Q4 2021 and bottomed at $111903.7 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Cardiol Therapeutics | 134.05 Mn | 134.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 111,903.70 |
| Dec 31, 2022 | 111,903.70 |
| Dec 31, 2021 | 204,425.25 |
| Dec 31, 2021 | 204,425.25 |